Review article: epidemiology and quality of life in functional gastrointestinal disorders

被引:251
作者
Chang, L [1 ]
机构
[1] Univ Calif Los Angeles, Ctr Neurovisceral Sci & Womens Hlth, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA
关键词
D O I
10.1111/j.1365-2036.2004.02183.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The epidemiology and health-related quality of life associated with functional gastrointestinal disorders are reviewed, with particular emphasis on irritable bowel syndrome and functional dyspepsia. The literature supports the significant world-wide prevalence of functional gastrointestinal disorders, including irritable bowel syndrome (IBS), functional dyspepsia and chronic constipation. An increased female prevalence has been demonstrated in most studies in patients with IBS and chronic constipation, but not functional dyspepsia. The female to male ratio appears to be greater in the health care-seeking population than in community populations. However, some differences in the reported general prevalence and gender-related prevalence of functional gastrointestinal disorders may be due to cultural factors and study methodology. A significant health care burden is associated with IBS, with increased out-patient services, abdominal and pelvic surgeries, and gastrointestinal- and non-gastrointestinal-related physician visits and health care costs. Health-related quality of life is impacted significantly in patients with functional gastrointestinal disorders, such as functional dyspepsia and IBS, compared with the general healthy population, as well as patients with other chronic medical conditions, such as gastro-oesophageal reflux disease and asthma. Impaired health-related quality of life has been demonstrated, in particular, in patients with moderate to severe disease seen in referral settings. The health-related quality of life appears to improve in treatment responders, or correlates with symptom improvement, with at least some treatment modalities studied in functional gastrointestinal disorders, but further studies are needed. Predictors of health-related quality of life in patients with functional gastrointestinal disorders include psychosocial factors, such as early adverse life events, and symptoms related to visceral perception, e.g. pain and chronic stress. The presence of extra-intestinal symptoms appears to have a major if not greater impact on health care visits, excess health care costs and health-related quality of life in patients with functional gastrointestinal disorders.
引用
收藏
页码:31 / 39
页数:9
相关论文
共 67 条
[1]  
*AM GASTR ASS, 2002, BURD GASTR DIS
[2]  
Amer College Gastroenterology Func, 2002, AM J GASTROENTEROL, V97, pS1
[3]   MENTAL PRECURSORS OF MYOCARDIAL-INFARCTION [J].
APPELS, A .
BRITISH JOURNAL OF PSYCHIATRY, 1990, 156 :465-471
[4]   Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria [J].
Badia, X ;
Mearin, F ;
Balboa, A ;
Baró, E ;
Caldwell, E ;
Cucala, M ;
Díaz-Rubio, M ;
Fueyo, A ;
Ponce, J ;
Roset, M ;
Talley, NJ .
PHARMACOECONOMICS, 2002, 20 (11) :749-758
[5]   Effect of childhood adversity on health related quality of life in patients with upper abdominal or chest pain [J].
Biggs, AM ;
Aziz, Q ;
Tomenson, B ;
Creed, F .
GUT, 2004, 53 (02) :180-186
[6]   Long-term improvement in functional dyspepsia using hypnotherapy [J].
Calvert, EL ;
Houghton, LA ;
Cooper, P ;
Morris, J ;
Whorwell, PJ .
GASTROENTEROLOGY, 2002, 123 (06) :1778-1785
[7]   Management of the irritable bowel syndrome [J].
Camilleri, M .
GASTROENTEROLOGY, 2001, 120 (03) :652-668
[8]   Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial [J].
Camilleri, M ;
Northcutt, AR ;
Kong, S ;
Dukes, GE ;
McSorley, D ;
Mangel, AW .
LANCET, 2000, 355 (9209) :1035-1040
[9]   A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome [J].
Camilleri, M ;
Chey, WY ;
Mayer, EA ;
Northcutt, AR ;
Heath, A ;
Dukes, GE ;
McSorley, D ;
Mangel, AM .
ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (14) :1733-1740
[10]  
Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149